003520 — Yungjin Pharm Co Income Statement
0.000.00%
- KR₩423bn
- KR₩474bn
- KR₩235bn
- 52
- 14
- 23
- 16
Annual income statement for Yungjin Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 220,516 | 208,464 | 196,067 | 218,381 | 234,902 |
Cost of Revenue | |||||
Gross Profit | 79,773 | 73,463 | 57,936 | 64,734 | 72,121 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 210,534 | 208,094 | 209,944 | 239,858 | 235,780 |
Operating Profit | 9,982 | 370 | -13,877 | -21,477 | -877 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 9,402 | 241 | -14,144 | -22,813 | -3,918 |
Provision for Income Taxes | |||||
Net Income After Taxes | 5,030 | -133 | -11,582 | -21,961 | -3,876 |
Net Income Before Extraordinary Items | |||||
Net Income | 5,030 | -133 | -11,582 | -21,961 | -3,876 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 5,030 | -133 | -11,582 | -21,961 | -3,876 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 28 | -0.6 | -62.8 | -68.1 | -5.88 |
Dividends per Share |